BUW Stock Overview
Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BUW from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Bio-Rad Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$298.00 |
| 52 Week High | US$322.00 |
| 52 Week Low | US$252.00 |
| Beta | 0.90 |
| 1 Month Change | -1.32% |
| 3 Month Change | 7.19% |
| 1 Year Change | n/a |
| 3 Year Change | -52.70% |
| 5 Year Change | n/a |
| Change since IPO | -37.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| BUW | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.6% | -1.4% | -1.6% |
| 1Y | n/a | -5.5% | 6.8% |
Return vs Industry: Insufficient data to determine how BUW performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how BUW performed against the German Market.
Price Volatility
| BUW volatility | |
|---|---|
| BUW Average Weekly Movement | 2.9% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BUW has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BUW's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 8,030 | Norman Schwartz | www.bio-rad.com |
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Bio-Rad Laboratories, Inc. Fundamentals Summary
| BUW fundamental statistics | |
|---|---|
| Market cap | €8.88b |
| Earnings (TTM) | -€749.02m |
| Revenue (TTM) | €2.48b |
3.6x
P/S Ratio-11.9x
P/E RatioIs BUW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BUW income statement (TTM) | |
|---|---|
| Revenue | US$2.58b |
| Cost of Revenue | US$1.17b |
| Gross Profit | US$1.41b |
| Other Expenses | US$2.19b |
| Earnings | -US$778.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -27.81 |
| Gross Margin | 54.54% |
| Net Profit Margin | -30.18% |
| Debt/Equity Ratio | 15.9% |
How did BUW perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 09:04 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio-Rad Laboratories, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Jon Wood | BofA Global Research |
| Sel Hardy | CFRA Equity Research |